{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:07:16Z","timestamp":1760267236320},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.arteri.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T04:43:16Z","timestamp":1371184996000},"page":"92-97","source":"Crossref","is-referenced-by-count":1,"title":["Estrategias terap\u00e9uticas. Evoluci\u00f3n y estado actual de las Gu\u00edas Europeas de Prevenci\u00f3n Cardiovascular"],"prefix":"10.1016","volume":"25","author":[{"given":"Carlos","family":"Guijarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan de Dios","family":"Garc\u00eda-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2013.05.004_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2013.05.004_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2012.05.007","volume":"223","author":"Perk","year":"2012","journal-title":"Atherosclerosis"},{"issue":"Suppl 2","key":"10.1016\/j.arteri.2013.05.004_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: Full text","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.arteri.2013.05.004_bib0020","first-page":"124","article-title":"Gu\u00eda Europea de Prevenci\u00f3n Cardiovascular en la Pr\u00e1ctica Cl\u00ednica. Adaptaci\u00f3n Espa\u00f1ola del CEIPC 2008","volume":"21","author":"Lobos","year":"2009","journal-title":"Clin Invest Arter"},{"key":"10.1016\/j.arteri.2013.05.004_bib0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2013.05.004_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. The Expert Panel","volume":"148","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.arteri.2013.05.004_bib0035","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2013.05.004_bib0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2013.05.004_bib0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: The Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2013.05.004_bib0050","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/eurheartj\/ehq205","article-title":"How to calculate vascular age with the SCORE project scales: A new method of cardiovascular risk evaluation","volume":"31","author":"Cuende","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2013.05.004_bib0060","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2013.05.004_bib0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170.000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2013.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2013.05.004_bib0075","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2013.05.004_bib0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25.673 high-risk patients of ER niacin\/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"Haynes","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2013.05.004_bib0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMp1106688","article-title":"Fibrates in the treatment of dyslipidemias \u2014 Time for a reassessment","volume":"365","author":"Goldfine","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2013.05.004_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.hipert.2013.01.002","article-title":"Los fibratos en el control del s\u00edndrome metab\u00f3lico","author":"Guijarro","year":"2013","journal-title":"Hipertens Riesgo Vasc"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916813000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916813000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T08:27:28Z","timestamp":1539592048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916813000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0214916813000326"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2013.05.004","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}